Rani Therapeutics (RANI) vs Rallybio (RLYB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Rallybio (RLYB) has outperformed Rani Therapeutics (RANI) over the past year, gaining 280.4% versus a loss of 60.9%. Over five years, RLYB leads with a -87.5% price change compared with -96.5% for RANI. Rani Therapeutics is the larger company by market cap ($90.0 million vs $86.5 million), about 1.0 times the size.
Rallybio converts more of its revenue into profit, with a net margin of -1046.4% versus -1817.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RANI | RLYB |
|---|---|---|
| Share price | $0.6406 | $16.28 |
| Market cap | $90.02M | $86.49M |
| 1-day change | -5.79% | -2.95% |
| YTD return | -52.55% | +196.65% |
| 1-year return | -60.94% | +280.37% |
| 5-year return | -96.54% | -87.46% |
| P/E ratio (TTM) | — | 2.03 |
| EPS (TTM) | $-0.15 | $8.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.63M | $858.00K |
| Revenue growth (YoY) | +58.85% | +34.91% |
| Net income (latest FY) | $-29.67M | $-8.98M |
| Operating margin | -2345.99% | -3853.61% |
| Net margin | -1817.09% | -1046.39% |
| 52-week high | $3.87 | $17.57 |
| 52-week low | $0.613 | $3.67 |
| Distance from 52-week high | -83.45% | -7.36% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +1023.95% | — |
| Average volume | 720.45K | 15.38K |
| Shares outstanding | 115.42M | 5.31M |
| Employees | 69 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RLYB has outperformed RANI by 341.3 percentage points over the past year.
- Rallybio is more profitable, keeping -1046.4 cents of every revenue dollar as net income versus -1817.1 cents for Rani Therapeutics.
- Rani Therapeutics grew revenue faster in its latest fiscal year (+58.85% vs +34.91%).
About Rani Therapeutics
RANI stock →Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
About Rallybio
RLYB stock →Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
RANI vs RLYB FAQ
Which is bigger, Rani Therapeutics or Rallybio?
Rani Therapeutics (RANI) is larger, with a market capitalization of $90.02M compared with $86.49M for Rallybio (RLYB).
Which stock has performed better over the past year, RANI or RLYB?
RLYB returned +280.37% over the past 12 months, compared with -60.94% for RANI (price return, excluding dividends). Past performance does not predict future results.
Are Rani Therapeutics and Rallybio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.